NVCT
Nuvectis Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.49
+0.49%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.9x
Market Cap
$799.45M
MomentumView details →
1D Return
+0.49%
YTD Return
+230.06%
RSI (14)
63.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.9x
Market Cap
$799.45M
RSI (14)
63.4
MomentumView details →
1D Return
+0.49%
YTD Return
+230.06%
SummaryUpdated Jun 1, 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Fort Lee, New Jersey. The company went public in February 2022 and focuses on developing precision medicines to treat serious unmet medical needs in oncology. Nuvectis operates as a research and development-focused biotech firm with two primary drug candidates in its pipeline, targeting novel pathways in cancer treatment.
Similar companies
Latest newsMore news →
Nuvectis Pharma reported a net loss of $7.0 million for Q2 2026, compared to a net loss of $6.3 million in Q2 2025.32d agoNuvectis Pharma, Inc. announced an underwritten public offering of its common stock, with an option for underwriters to purchase additional shares.67d agoNuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 and NXP200.74d ago